{"id":"https://openalex.org/W3097682133","doi":"https://doi.org/10.1182/blood-2020-136880","title":"Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351","display_name":"Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3097682133","doi":"https://doi.org/10.1182/blood-2020-136880","mag":"3097682133"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-136880","doi":"https://doi.org/10.1182/blood-2020-136880","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-136880","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5114046358","display_name":"Meagan A. Jacoby","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meagan A. Jacoby","raw_affiliation_strings":["Washington University School of Medicine, St. Louis, MO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University School of Medicine, St. Louis, MO","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023290487","display_name":"Laura Elizabeth Finn","orcid":"https://orcid.org/0000-0002-4980-8997","observed_orcids":["https://orcid.org/0000-0002-4980-8997"]},"institutions":[{"id":"https://openalex.org/I1336053918","display_name":"Ochsner Health System","ror":"https://ror.org/003ngne20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1336053918"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura E. Finn","raw_affiliation_strings":["Ochsner Health, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ochsner Health, New Orleans, LA","institution_ids":["https://openalex.org/I1336053918"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018403340","display_name":"Ashkan Emadi","orcid":"https://orcid.org/0000-0003-3769-3210","observed_orcids":["https://orcid.org/0000-0003-3769-3210"]},"institutions":[{"id":"https://openalex.org/I4390039317","display_name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","ror":"https://ror.org/01vft3j45","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I14285509","https://openalex.org/I4390039317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashkan Emadi","raw_affiliation_strings":["Division of Hematology and Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD","institution_ids":["https://openalex.org/I4390039317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015561659","display_name":"Nakhle S. Saba","orcid":"https://orcid.org/0000-0003-3206-2575","observed_orcids":["https://orcid.org/0000-0003-3206-2575"]},"institutions":[{"id":"https://openalex.org/I114832834","display_name":"Tulane University","ror":"https://ror.org/04vmvtb21","country_code":"US","type":"education","lineage":["https://openalex.org/I114832834"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nakhle S. Saba","raw_affiliation_strings":["Tulane University School of Medicine, New Orleans, LA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tulane University School of Medicine, New Orleans, LA","institution_ids":["https://openalex.org/I114832834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109344899","display_name":"Bayard L. Powell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1282516798","display_name":"Atrium Health Wake Forest Baptist","ror":"https://ror.org/04v8djg66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282516798","https://openalex.org/I47251452"]},{"id":"https://openalex.org/I4387930303","display_name":"Wake Forest Baptist Comprehensive Cancer Center","ror":"https://ror.org/0512csj88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282516798","https://openalex.org/I4387930303","https://openalex.org/I47251452"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bayard L. Powell","raw_affiliation_strings":["Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC","institution_ids":["https://openalex.org/I1282516798","https://openalex.org/I4387930303"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084409602","display_name":"Karen P. Seiter","orcid":"https://orcid.org/0000-0003-3838-7901","observed_orcids":["https://orcid.org/0000-0003-3838-7901"]},"institutions":[{"id":"https://openalex.org/I181190671","display_name":"New York Medical College","ror":"https://ror.org/03dkvy735","country_code":"US","type":"education","lineage":["https://openalex.org/I181190671"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen P. Seiter","raw_affiliation_strings":["New York Medical College, Valhalla, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New York Medical College, Valhalla, NY","institution_ids":["https://openalex.org/I181190671"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082261813","display_name":"Rosella Garcia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101297","display_name":"Jazz Pharmaceuticals (United States)","ror":"https://ror.org/019rsbe67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101297","https://openalex.org/I4210152300"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rosella Garcia","raw_affiliation_strings":["Jazz Pharmaceuticals, Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jazz Pharmaceuticals, Palo Alto, CA","institution_ids":["https://openalex.org/I4210101297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026347795","display_name":"Stefan Faderl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101297","display_name":"Jazz Pharmaceuticals (United States)","ror":"https://ror.org/019rsbe67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101297","https://openalex.org/I4210152300"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stefan Faderl","raw_affiliation_strings":["Jazz Pharmaceuticals, Palo Alto, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jazz Pharmaceuticals, Palo Alto, CA","institution_ids":["https://openalex.org/I4210101297"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079303033","display_name":"Heather Jean Male","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128618","display_name":"University of Kansas Medical Center","ror":"https://ror.org/036c9yv20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210128618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Heather J. Male","raw_affiliation_strings":["University of Kansas Medical Center, Kansas City, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Kansas Medical Center, Kansas City, KS","institution_ids":["https://openalex.org/I4210128618"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"136","issue":"Supplement 1","first_page":"19","last_page":"19"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.8916000127792358,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.8916000127792358,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.03629999980330467,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.021400000900030136,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cpx-351","display_name":"CPX-351","score":0.9850000143051147},{"id":"https://openalex.org/keywords/vyxeos","display_name":"Vyxeos","score":0.902999997138977},{"id":"https://openalex.org/keywords/daunorubicin","display_name":"daunorubicin","score":0.8180000185966492},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.972000002861023},{"id":"https://openalex.org/keywords/liposomal-chemotherapy","display_name":"liposomal chemotherapy","score":0.9179999828338623},{"id":"https://openalex.org/keywords/therapy-related-acute-myeloid-leukemia","display_name":"therapy-related acute myeloid leukemia","score":0.925000011920929},{"id":"https://openalex.org/keywords/aml-with-myelodysplasia-related-changes","display_name":"AML with myelodysplasia-related changes","score":0.9629999995231628},{"id":"https://openalex.org/keywords/infusion-related-reactions","display_name":"infusion reactions","score":0.9769999980926514},{"id":"https://openalex.org/keywords/post-marketing-surveillance","display_name":"post-marketing surveillance","score":0.6389999985694885},{"id":"https://openalex.org/keywords/induction-chemotherapy","display_name":"induction chemotherapy","score":0.5590000152587891},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5619999766349792},{"id":"https://openalex.org/keywords/adult-patients","display_name":"adult patients","score":0.37400001287460327}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8724133968353271},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.7248965501785278},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6225346326828003},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5605188608169556},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.541661262512207},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5222164392471313},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.4519750773906708},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.4400692582130432},{"id":"https://openalex.org/C88879693","wikidata":"https://www.wikidata.org/wiki/Q217690","display_name":"Cumulative incidence","level":3,"score":0.429782509803772},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.3930293917655945},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.38199329376220703},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35598671436309814},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.28958824276924133},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.22885268926620483},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-136880","doi":"https://doi.org/10.1182/blood-2020-136880","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-136880","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3161521076","https://openalex.org/W4417020015","https://openalex.org/W2970749325","https://openalex.org/W2986130636","https://openalex.org/W2976760128","https://openalex.org/W2909182124","https://openalex.org/W2989177065","https://openalex.org/W3213367711","https://openalex.org/W3096295699","https://openalex.org/W2989072751"],"abstract_inverted_index":{"Introduction:":[0],"CPX-351":[1,80,172,192,210,227,419,585],"(Vyxeos\u00ae;":[2],"daunorubicin":[3,14,239,437],"and":[4,15,30,108,164,201,238,250,280,288,325,378,381,393,445,479,515,538,556,589,617,635,648,708],"cytarabine":[5,16,446],"liposome":[6],"for":[7,32,62,289],"injection),":[8],"a":[9,18,74,104,125,422,434],"dual-drug":[10],"liposomal":[11,140],"encapsulation":[12],"of":[13,35,51,77,116,166,232,261,282,295,307,318,370,383,390,398,403,424,439,448,505,608,614,639,644,702,715,724],"in":[17,173,356,568,602,623,657,671,790,798],"synergistic":[19],"1:5":[20],"molar":[21],"ratio,":[22],"has":[23],"been":[24,206],"approved":[25,198],"by":[26,149,160,242,534],"the":[27,33,52,60,63,118,130,150,156,162,188,197,229,252,257,262,293,305,308,315,319,343,357,461,475,489,526,575,606,618,640,646,666,672],"US":[28,199],"FDA":[29,151],"EMA":[31],"treatment":[34,272,567],"adults":[36,174],"with":[37,44,68,103,124,129,139,171,175,209,226,368,421,604,654,677],"newly":[38,69],"diagnosed,":[39],"therapy-related":[40],"AML":[41,43,658],"or":[42,211,337,342,409,503,522,704,717,726],"myelodysplasia-related":[45],"changes.":[46],"The":[47,278,359,463,493],"primary":[48,131],"endpoint":[49,132],"analysis":[50],"pivotal":[53,673],"phase":[54,157,674],"3":[55,158,418,491,521,675],"study":[56,145,159,183,528,576,601,627],"(NCT01696084)":[57],"that":[58],"formed":[59],"basis":[61],"approvals":[64],"evaluated":[65,286],"older":[66],"patients":[67,218,267,353,371,384,399,414,511,518,537,603,659],"diagnosed":[70],"high-risk/secondary":[71],"AML;":[72],"after":[73,292,314,474,488,566,637],"median":[75,83,120,360,435],"follow-up":[76],"20.7":[78],"months,":[79],"significantly":[81],"improved":[82,119],"overall":[84],"survival":[85],"(OS)":[86],"versus":[87],"conventional":[88],"7+3":[89],"(9.56":[90],"vs":[91],"5.95":[92],"months;":[93],"HR":[94,126],"=":[95,543,559,592],"0.69":[96],"[95%":[97],"CI:":[98],"0.52,":[99],"0.90];":[100],"1-sidedP=":[101],"0.003),":[102],"comparable":[105],"safety":[106,668,680],"profile":[107,669],"2":[109,471,481,544,569],"infusion-related":[110,167,283,458,494,609],"reaction":[111],"events.":[112],"After":[113],"5":[114],"years":[115,221,364],"follow-up,":[117],"OS":[121],"was":[122,146,179,193,345,362,611],"maintained,":[123],"(0.70)":[127],"consistent":[128,653],"analysis.":[133],"Infusion-related":[134],"reactions":[135,168,284,459,495,610,619],"are":[136],"generally":[137],"common":[138],"drugs;":[141],"this":[142,598,626],"post-marketing":[143,599],"observational":[144,600],"therefore":[147],"requested":[148],"to":[152,186,190,223,328,347,499,579,584],"confirm":[153],"observations":[154],"from":[155,304],"assessing":[161],"incidence":[163,279],"severity":[165,281],"during":[169,287,460,574,634],"induction":[170,225,264,321,642,661],"AML.":[176],"Methods:":[177],"This":[178],"an":[180,386,699,712,721],"observational,":[181],"single-arm":[182],"(NCT03526926);":[184],"prior":[185,667],"enrollment,":[187],"decision":[189],"prescribe":[191],"made":[194],"based":[195],"on":[196,246,469,483,631,698,711,720],"indications":[200],"dosing.":[202],"Patients":[203,432],"who":[204],"had":[205,385,400],"previously":[207],"treated":[208],"any":[212],"investigational":[213],"agent":[214],"were":[215,222,285,302,332,340,354,376,532,577,620,652],"ineligible.":[216],"Eligible":[217],"aged":[219,372],"\u226518":[220],"receive":[224],"at":[228,274],"label":[230],"dosage":[231],"100":[233,236],"units/m2":[234],"(cytarabine":[235],"mg/m2":[237],"44":[240],"mg/m2)":[241],"90-minute":[243],"IV":[244],"infusion":[245,310,317,638],"Days":[247],"1,":[248,392],"3,":[249],"5;":[251],"observation":[253],"period":[254],"included":[255,539],"only":[256,628],"first":[258,263,309,320,641],"6":[259,535],"days":[260],"cycle,":[265],"although":[266],"may":[268],"have":[269],"received":[270,416,433],"subsequent":[271],"cycles":[273],"their":[275],"physician's":[276],"discretion.":[277],"90":[290],"minutes":[291],"completion":[294],"each":[296],"infusion.":[297],"Treatment-emergent":[298],"adverse":[299,632],"events":[300,633],"(TEAEs)":[301],"collected":[303,629],"start":[306],"until":[311,334],"1":[312,467,477,560,593],"day":[313],"last":[316],"cycle":[322,643],"(Day":[323],"6)":[324],"graded":[326],"according":[327],"CTCAE":[329],"v4.03.":[330],"TEAEs":[331,524,531,564,581,647,650],"followed":[333],"resolution,":[335],"stabilization,":[336],"permanent":[338],"sequelae":[339],"identified,":[341],"patient":[344,428,456,464],"lost":[346],"follow-up.":[348],"Results:":[349],"In":[350,507,597],"total,":[351,508],"52":[352,615],"enrolled":[355],"study.":[358,462],"age":[361],"64":[363],"(range:":[365,442,451],"28,":[366],"78),":[367],"67%":[369],"\u226560":[373],"years;":[374],"56%":[375],"male;":[377],"23%,":[379],"46%,":[380],"23%":[382],"ECOG":[387],"performance":[388],"status":[389],"0,":[391],"2,":[394],"respectively.":[395],"A":[396],"majority":[397],"no":[401,678],"history":[402],"allergies":[404],"(64%),":[405],"allergic":[406],"asthma":[407],"(98%),":[408],"autoimmune":[410],"disorders":[411],"(87%).":[412],"Most":[413],"(94%)":[415],"all":[417],"infusions,":[420],"mean":[423],"2.9":[425],"infusions":[426],"per":[427],"(standard":[429],"deviation:":[430],"0.3).":[431],"cumulative":[436],"dose":[438,447,500],"247.5":[440],"mg":[441,450],"88,":[443],"339)":[444],"562.5":[449],"204,":[452],"774).":[453],"One":[454],"(2%)":[455],"experienced":[457,465,512,519],"grade":[466,480,520,621],"pyrexia":[468],"Day":[470,476,484,490],"(25":[472],"hours":[473,487],"infusion)":[478],"dyspnea":[482,557],"4":[485,523],"(21":[486],"infusion).":[492],"did":[496],"not":[497],"lead":[498],"change,":[501],"interruption,":[502],"discontinuation":[504],"treatment.":[506],"39":[509],"(75%)":[510],"any-grade":[513],"TEAEs,":[514],"13":[516],"(25%)":[517],"within":[525],"6-day":[527],"period.":[529],"Serious":[530],"reported":[533,573,651,670],"(12%)":[536],"respiratory":[540],"failure":[541],"(n":[542,558],"[4%]),":[545],"pyrexia,":[546],"lung":[547],"infection,":[548],"sepsis,":[549],"tumor":[550],"lysis":[551],"syndrome,":[552],"cerebrovascular":[553],"accident,":[554],"embolism,":[555],"[2%]":[561,594],"each);":[562],"serious":[563,580,649],"resolved":[565],"patients.":[570],"Three":[571],"deaths":[572],"due":[578],"considered":[582],"unrelated":[583],"(sepsis,":[586],"thromboembolic":[587],"event,":[588],"stroke;":[590],"n":[591],"each).":[595],"Conclusions:":[596],"AML,":[605],"frequency":[607],"low":[612],"(1":[613],"patients)":[616],"1-2":[622],"severity.":[624],"Although":[625],"data":[630,664],"immediately":[636],"CPX-351,":[645],"those":[655],"seen":[656],"receiving":[660],"chemotherapy.":[662],"These":[663],"support":[665],"study,":[676],"new":[679],"signals":[681],"identified.":[682],"Disclosures":[683],"Jacoby:":[684],"Jazz":[685],"Pharmaceuticals:Research":[686,694],"Funding;AbbVie:Research":[687],"Funding.Finn:Jazz":[688],"Pharmaceuticals:Speakers":[689],"Bureau;Celgene:Speakers":[690],"Bureau;Seattle":[691],"Genetics:Speakers":[692],"Bureau.Emadi:Jazz":[693],"Funding;NewLink":[695],"Genetics:Research":[696],"Funding;Amgen:Membership":[697],"entity's":[700,713,722],"Board":[701,714,723],"Directors":[703,716,725],"advisory":[705,718,727],"committees;KinaRx:Other:":[706],"co-founder":[707],"scientific":[709],"advisor;Genentech:Membership":[710],"committees;Servier:Membership":[719],"committees.Saba:Kyowa":[728],"Kirin:Other:":[729],"Advisory":[730,732,737,741,745],"Board;Janssen:Other:":[731],"Board,":[733,738,742],"Speakers":[734,739,743,767,769,771,775,779],"Bureau;AbbVie:Consultancy,":[735],"Other:":[736,750,755],"Bureau;Pharmacyclics:Other:":[740],"Bureau;Kite:Other:":[744],"Board.Powell:Pfizer:Research":[746],"Funding;Novartis:Research":[747],"Funding;Jazz":[748,763],"Pharmaceuticals:Consultancy,":[749,754],"Advisor,":[751,756],"Research":[752,757,765,773,777],"Funding;Rafael":[753],"Funding;Genentech:Research":[758],"Funding.Seiter:Alexion:Speakers":[759],"Bureau;AbbVie:Speakers":[760],"Bureau;Onconova:Research":[761],"Funding;Forma:Research":[762],"Pharmaceuticals:Honoraria,":[764],"Funding,":[766,774,778],"Bureau;Sanofi:Honoraria,":[768],"Bureau;Incyte:Honoraria,":[770],"Bureau;Celgene:Honoraria,":[772],"Bureau;Novartis:Honoraria,":[776],"Bureau;Sun":[780],"Pharma:Research":[781],"Funding;Roche:Research":[782],"Funding;Amphivena:Research":[783],"Funding.Garcia:Jazz":[784],"Pharmaceuticals:Current":[785,793],"Employment,":[786,794],"Current":[787,795],"equity":[788,796],"holder":[789,797],"publicly-traded":[791,799],"company.Faderl:Jazz":[792],"company.":[800]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2020-11-09T00:00:00"}